
West Bengal: Know How West Midnapore Residents Get Medicines At 90 % Discount Through Jan Aushadhi Kendras
Residents of West Bengal's West Midnapore district are increasingly benefiting from the Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP), a flagship initiative of the Central government aimed at making quality medicines affordable and accessible for all. Under the scheme, Jan Aushadhi Kendras have been established in various parts of the district, offering essential medicines at discounts ranging from 50 per cent to 90 per cent. These outlets are proving to be a lifeline for many, especially those from economically weaker sections.
The response from the public has been overwhelmingly positive. Locals said that the medicines available at the Kendras are not only affordable but also effective and reliable. Several such Kendras are already operational in West Midnapore, and there is growing demand for more to be opened in remote areas.
Santu Ghosh, an operator of one of the Kendras, shared his experience with IANS.
'I've been running this shop for a year now. Initially, people were hesitant as they were unfamiliar with generic medicines. But after advertisements, the response has been very good. For instance, paracetamol costs just Rs 15 for 15 tablets here. Outside, it's much costlier. The scheme offers medicines at a 50 per cent to 90 per cent discount. I thank the Prime Minister for this initiative, which helps common people access quality medicines at such low prices.'
Harvinder Singh, a regular customer, said: "I've been getting my medicines from here for some time now. It's really good. The quality is excellent,t and it's saving us a lot of money"
Launched in November 2008 by the Department of Pharmaceuticals under the Ministry of Chemicals and Fertilisers, the PMBJP aims to provide quality generic medicines through Jan Aushadhi Kendras across India. The scheme has gained momentum under the leadership of Prime Minister Narendra Modi, with thousands of such Kendras now operating nationwide.
To promote the use of generic medicines, March 7 is observed annually as 'Jan Aushadhi Diwas.' This year, a week-long campaign from March 1 to 7 featured events and awareness drives across the country, further encouraging people to make use of the Kendras.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Standard
34 minutes ago
- Business Standard
Zydus Lifesciences gets USFDA nod for Rifaximin tablets
Zydus Lifesciences announced that it has received tentative approval from the United States Food and Drug Administration (USFDA) for Rifaximin tablets, 550 mg, under the reference listed drug (RLD) Xifaxan tablets, 550 mg. Rifaximin tablets are indicated for the treatment of irritable bowel syndrome with diarrhoea (IBS-D) in adults. The tablets will be produced at the Group's manufacturing facility at SEZ II, Ahmedabad. According to IQVIA MAT 2025, Rifaximin tablets had annual sales of USD $2,672.9 million in the United States. The group now has 427 approvals and has filed 492 Abbreviated New Drug Applications (ANDAs) since the commencement of the filing process in FY 2003-04. The companys consolidated net profit shed 0.96% to Rs 1,170.9 crore on 17.21% rise in revenue from operations to Rs 6290.2 crore in Q4 FY25 over Q4 FY24. Zydus Lifesciences is a discovery-driven, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. Shares of Zydus Lifesciences shed 0.53% to Rs 924.95 on the BSE.


Time of India
38 minutes ago
- Time of India
Zydus gets USFDA nod for generic IBS-D treatment drug
Zydus Lifesciences on Monday said it has received approval from the US health regulator to market a drug for the treatment of irritable bowel syndrome with diarrhoea in adults. The company has received tentative approval from the US Food and Drug Administration (USFDA) for Rifaximin Tablets (550 mg), the drug manufacturing firm said in a regulatory filing. Rifaximin tablets are indicated for the treatment of irritable bowel syndrome with diarrhoea ( IBS-D ) in adults. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Access all TV channels anywhere, anytime Techno Mag Learn More Undo As per the IQVIA MAT March sales data, Rifaximin tablets had an annual sales of USD 2,672.9 million in the US. Shares of Zydus Lifesciences were trading at Rs 926.05 apiece, 0.41 per cent down from previous close, on BSE.


Business Standard
2 hours ago
- Business Standard
AstraZeneca Pharma soars after Q4 PAT jumps 48% YoY
AstraZeneca Pharma surged 10.03% to Rs 8764.05 after the company's standalone net profit rose 47.54% to Rs 58.25 crore, while revenue from operations rose 25.39% to Rs 480.48 crore in Q4 March 2025 over Q4 March 2024. Profit before tax (PBT) stood at Rs 78.47 crore in Q4 FY25, up 44.35% year-on-year, and up 86.74% quarter-on-quarter. Total expenses rose 22.22% to Rs 412.48 crore in Q4FY25 over Q4FY24. During the quarter, cost of materials consumed stood at Rs 94.25 crore (up 180.34% YoY) while employee benefits expense was at Rs 66.07 crore (up 13.95% YoY). The company's net profit surged 88.82% while net sales rose 9.13% in Q4 March 2025 over Q3 December 2024. For the full year FY25, revenue from operations rose 32.48% to Rs 1,716.29 crore, while net profit fell 28.34% to Rs 115.74 crore. PBT fell 28.78% to Rs 156.36 crore compared to FY24. The company's standalone net cash from operating activities stood at Rs 65.36 crore in FY25, as against Rs 27.87 crore in FY24. Dr. Sanjeev Panchal, country president & managing director of the company, said, "Our company delivered strong growth in Financial Year 2024-25 by launching innovative medicines in India, giving us momentum into 2025 and beyond. We are pleased to share that our company has, for the first time, crossed the INR 1,700 crore mark ($200 million)." The board recommended dividend of Rs 32 per equity share for FY25. AstraZeneca is a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines in four areas: Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Rare Diseases. It operates in over 100 countries.